| Assessment Status | Rapid Review complete |
| HTA ID | 24037 |
| Drug | Aztreonam-avibactam |
| Brand | Emblaveo® |
| Indication | For the treatment of the following infections in adult patients: • Complicated intra-abdominal infection (cIAI) • Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritis. Aztreonam-avibactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. |
| Assessment Process | |
| Rapid review commissioned | 23/09/2024 |
| Rapid review completed | 25/10/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that aztreonam-avibactam not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. August 2025